BDUUF vs JNJ: Which Stock is Better?
Side-by-side comparison of Bangkok Dusit Medical Services Public Company Limited and Johnson & Johnson in 2026
BDUUF
Bangkok Dusit Medical Services Public Company Limited
$0.65
JNJ
Johnson & Johnson
$230.69
Key Metrics Comparison
| Metric | BDUUF | JNJ | Winner |
|---|---|---|---|
| Market Cap | $10.33B | $564.35B | JNJ |
| P/E Ratio | 21.67 | 21.23 | JNJ |
| EPS (TTM) | $0.03 | $11.03 | JNJ |
| Revenue Growth | 0.0% | 0.1% | JNJ |
| Gross Margin | 37.1% | 68.0% | JNJ |
Analyze BDUUF
Full quant analysis
Analyze JNJ
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is BDUUF or JNJ a better investment?
Comparing BDUUF and JNJ: Bangkok Dusit Medical Services Public Company Limited has a market cap of $10.33B while Johnson & Johnson has $564.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between BDUUF and JNJ?
BDUUF (Bangkok Dusit Medical Services Public Company Limited) and JNJ (Johnson & Johnson) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: BDUUF or JNJ?
Based on P/E ratios, JNJ trades at a lower multiple (21.2x vs 21.7x).
Which is growing faster: BDUUF or JNJ?
JNJ has higher revenue growth at 0.1% vs 0.0% for BDUUF.
Which company is more profitable: BDUUF or JNJ?
Johnson & Johnson (JNJ) has higher gross margins at 68.0% compared to 37.1% for BDUUF.
Which is the larger company: BDUUF or JNJ?
Johnson & Johnson (JNJ) is larger with a market cap of $564.35B compared to $10.33B for BDUUF.
Should I buy BDUUF or JNJ in 2026?
Both BDUUF and JNJ have investment merit. BDUUF trades at $0.65 while JNJ trades at $230.69. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between BDUUF and JNJ stock?
Key differences: Market Cap ($10.33B vs $564.35B), P/E Ratio (21.7x vs 21.2x), Revenue Growth (0.0% vs 0.1%), Gross Margin (37.1% vs 68.0%).